Anti-EBOV Antibody (Atoltivimab)
Catalog No.
F1037
Anti-EBOV Antibody (Atoltivimab)
Featured Products
Atoltivimab (REGN3470) and maftivimab/odesivimab (Inmazeb) are the first monoclonal antibodies approved by the U.S. Food and Drug Administration (FDA) for the treatment of Zaire ebolavirus (EBOV) infection.
145 kDa
Dry ice
2135632-29-8
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
REGN 3470
100 mM Pro 20 mM Arg pH 5.0. No preservative!
Human
Unconjugated
Monoclonal
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
EBOV
Please avoid freeze-thaw cycles.